Evidence map›Paper›PMID 42737106›Full record

ReviewPolymers2026

Localized Hydrogel-Based Therapeutics: A Strategic Approach to Mitigating Postoperative Recurrence in Breast Cancer.

Kiran Kainat, Muhammad Saif Ur Rahman, Muhammad Shoaib, Shanshan Xu

Abstract readReview
In one paragraph

Review in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kiran KainatInstitute for Advanced Study, Shenzhen University, Shenzhen 518060, China.
Muhammad Saif Ur RahmanInstitute for Advanced Study, Shenzhen University, Shenzhen 518060, China.
Muhammad ShoaibSustainable Materials Research Center (SUSMAT-RC), College of Chemical Sciences and Engineering (CCSE), Mohammed VI Polytechnic University (UM6P), Benguerir 43150, Morocco.ORCID 0000-0002-2008-9925
Shanshan XuInstitute for Advanced Study, Shenzhen University, Shenzhen 518060, China.

Funding

Ningbo Science and Technology Bureau 2024Z033Shenzhen Medical Research Fund D2402004Talent Development Foundation of The First Dongguan Affiliated Hospital of Guangdong Medical University PU2024005
6 · The paper itself

Abstract

Cancer remains one of the leading causes of death globally, and breast cancer is the most frequently diagnosed cancer in women. Even though surgical excision is the main treatment of solid tumors, recurrence and metastasis to another location postoperatively provide lasting therapeutic challenges. Systemic adverse effects and a lack of sufficient drug bioavailability at the resection site can often hinder traditional adjuvant modalities, especially chemotherapy and radiotherapy. To address these drawbacks, localized drug delivery platforms have gained a lot of interest, and hydrogels have emerged as highly beneficial systems. Hydrogels are three-dimensional hydrophilic polymer networks that can be designed to be injectable and in situ-forming. They can be engineered to fit irregular surgical cavities and deliver therapeutics in a long-lasting, controlled manner. The current literature review outlines the clinical issue of tumor recurrence following surgery with a special focus on breast cancer and evaluates hydrogel-based methods of site-specific therapy. We outline the categorization, assembly, and functionalization of hydrogel systems based on natural, synthetic, and hybrid polymers, and reflect on advanced stimuli-responsive and cell-targeted formulations in the context of cancer immunotherapy. This paper presents the translational applications of hydrogel platforms to enhance postoperative management and prevent tumor recurrence by combining new advances.

Indexed as

biomaterialsbreast cancercancerhydrogelsimmunotherapylocal drug deliverypostoperative recurrence

Identifiers

PMID42737106
PMCPMC13567975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.